首页> 外文期刊>Eye >Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularisation secondary to punctate inner choroidopathy.
【24h】

Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularisation secondary to punctate inner choroidopathy.

机译:光动力疗法联合全身性皮质类固醇治疗点状内脉络膜病变继发的脉络膜新生血管。

获取原文
获取原文并翻译 | 示例
       

摘要

AimTo report on visual acuity (VA) and angiographic outcomes in patients presenting with subfoveal choroidal neovascular membranes (CNV) secondary to punctate inner choroidopathy (PIC), treated with photodynamic therapy (PDT) with verteporfin combined with systemic corticosteroids.MethodsA prospective case series of patients with subfoveal CNV secondary to PIC was analysed. All patients were treated with PDT combined with oral prednisolone (1 mg/kg body weight/day) which was started 5 days before PDT. Fluorescein angiography was performed at baseline and every 3 months post-treatment to establish the size, position, and activity of the CNV. Visual acuity was measured using the ETDRS scale. Further PDT treatment was carried out at follow-up visits if there was angiographic evidence of ongoing CNV activity.ResultsFive female patients with a mean age of 30.4 years (range 25-43 years) were treated over a 12-month period. The mean greatest linear diameter (GLD) of the CNV was 1.66 mm (range 0.46-3.28 mm). Amean improvement in vision of nine ETDRS letters (range -15-20 letters) after treatment was found, which was maintained at final follow-up. The mean follow-up time was 12 months (range 10-14 months). The mean number of PDT treatments was two (range 1-3).Conclusions:The vaso-occlusive effect of PDT combined with the vasostatic and anti-inflammatory effect of systemic oral prednisolone appears to be a safe and effective option in the primary treatment of subfoveal CNV in patients with PIC.Eye (2008) 22, 528-533; doi:10.1038/sj.eye.6702688; published online 19 January 2007.
机译:目的报告患有点状内脉络膜病变(PIC)继发点状脉络膜下新生血管膜(CNV)的患者的视敏度(VA)和血管造影结果,并采用光动力疗法(PDT)联合维替泊芬联合全身性皮质类固醇治疗。分析了继发于PIC的小凹下CNV患者。所有患者均在PDT前5天开始接受PDT联合口服泼尼松龙(1 mg / kg体重/天)治疗。在基线以及治疗后每3个月进行一次荧光素血管造影,以确定CNV的大小,位置和活性。使用ETDRS量表测量视力。如果有持续的CNV活动的血管造影证据,则在随访中进一步进行PDT治疗。结果5名平均年龄为30.4岁(25-43岁)的女性患者接受了12个月的治疗。 CNV的平均最大线性直径(GLD)为1.66毫米(范围为0.46-3.28毫米)。发现治疗后9个ETDRS字母(-15-20字母)的视力有所改善,并在最终随访中得以维持。平均随访时间为12个月(范围10-14个月)。 PDT的平均治疗次数为2次(范围1-3)。结论:PDT的血管闭塞作用与全身性泼尼松龙的血管抑制和抗炎作用相结合似乎是一种安全有效的选择PIC患者的中央凹下CNV.Eye(2008)22,528-533; doi:10.1038 / sj.eye.6702688;在线发布于2007年1月19日。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号